GlassScriptPhysician profile
Parthiv Amin
NPI 1164650834
$6,652.66
in general payments reported to CMS, 2019-2025
44 companies · $344 in 2025
The $344 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,008 · 2020: $3,402 · 2021: $659 · 2022: $392 · 2023: $375 · 2024: $472 · 2025: $344.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,191.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,190.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $2,600.00 | 2020 | |
| Abbott Laboratories | $526.60 | 2019-2025 | Aveir, Xience Sierra |
| Novartis Pharmaceuticals Corporation | $456.36 | 2019-2025 | |
| Abiomed | $302.85 | 2022-2025 | Impella |
| Medtronic, INC. | $280.36 | 2021-2023 | Linq II |
| Shockwave Medical, INC | $261.10 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $256.30 | 2019-2025 | Camzyos |
| Janssen Pharmaceuticals, INC | $215.00 | 2019-2023 | Xarelto |
| Pfizer INC. | $177.19 | 2019-2025 | |
| Avinger INC. | $144.95 | 2021 | |
| Penumbra, INC. | $142.80 | 2022 | |
| Edwards Lifesciences Corporation | $129.99 | 2021 | |
| Amgen INC. | $97.63 | 2019-2023 | Repatha |
| Novo Nordisk INC | $81.88 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Boston Scientific Corporation | $80.48 | 2019-2023 | Lux-Dx Insertable Cardiac Monitor, Varithena Administration Pack |
Show all 42 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Parthiv Amin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.